Nuformix (LON:NFX) Posts Earnings Results

Nuformix (LON:NFX) announced its earnings results on Wednesday. The company reported GBX (0.46) (($0.01)) EPS for the quarter, Digital Look Earnings reports.

Nuformix Trading Down 24.1 %

Shares of Nuformix stock traded down GBX 0.04 ($0.00) on Wednesday, reaching GBX 0.11 ($0.00). 487,028,406 shares of the company’s stock were exchanged, compared to its average volume of 79,448,063. The company has a market capitalization of £901,241.00, a P/E ratio of -1.63 and a beta of 1.22. Nuformix has a 52 week low of GBX 0.04 ($0.00) and a 52 week high of GBX 0.34 ($0.00). The company has a debt-to-equity ratio of 1.17, a quick ratio of 3.35 and a current ratio of 1.12. The firm’s 50-day moving average is GBX 0.06 and its two-hundred day moving average is GBX 0.10.

Nuformix Company Profile

Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis.